000			03163cam a2200349 a 4500
003			EG-GiCUC
005			20250223032833.0
008			211023s2021 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aPh.D
099			_aCai01.11.31.Ph.D.2021.Mo.E
100	0		_aMohammed Mahmoud Abdelhamid Ali
245	1	0	_aEffect of hepatic fat fraction on major hepatocellular carcinoma features at magnetic resonance imaging / _cMohammed Mahmoud Abdelhamid Ali ; Supervised Mohamed Fouad Osman , Bahaa Eldin Mahmoud Hussein , Ahmed Ramadan Mohammed
246	1	5	_aتأثير مرض الكبد الدهنى على الخصائص الأساسية لسرطان الكبد فى فحص الرنين المغناطيسى
260			_aCairo : _bMohammed Mahmoud Abdelhamid Ali , _c2021
300			_a133 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Radio-diagnosis
520			_aBackground: Hepatocellular carcinoma (HCC) is the fifth most frequent cancer on the world. Fat accumulation within hepatocytes is known as hepatic steatosis. In recent years, research has found that people with non- alcoholic fatty liver disease have a higher chance of developing HCC. The LI-RADS® (Liver Imaging Reporting and Data System) was created to facilitate consistent reporting of imaging findings in patients at risk of HCC. The purpose of this study was to see how hepatic fat fraction affected the LI-RADS major HCC features on MRI. Methods: This study comprised 92 patients who underwent a liver MRI with MRI findings consistent with HCC (LIRADS V). Readers assessed hepatic parenchyma characteristics as well as MRI HCC features including: major HCC features, ancillary features favoring malignancy and ancillary features favoring HCC in particular. Hepatic fat signal fraction was calculated using the formula: fat fraction = [(SIP-SOP) / 2*SIP)]. We categorize the patients into two groups: 1) HCC with hepatic steatosis group (Hepatic FS fraction {u2265} 5% at MRI). 2) HCC with no hepatic steatosis group: (Hepatic FS fraction > 5% at MRI). Results: All HCC (92/92; 100%) showed arterial phase hyperenhancement (APHE), however, it was found that there was a significant association between hepatic steatosis and late APHE. Encapsulation was observed in 51 HCC (55.4 %); in hepatic steatosis patients 17 HCC (37.8 %) displayed enhancing capsule, compared to 34 HCC (72.3 %) in patients with no hepatic steatosis.The HCC size ranged from 11 - 200 mm (Mean ± SD = 42.2 ± 51.8) in the hepatic steatosis group, however in patients with negative hepatic steatosis the size ranged from 13 - 205 (Mean ± SD = 62.9 ± 54.5)
530			_aIssued also as CD
653		4	_aHCC
653		4	_aHepatic steatosis
653		4	_aLI-RADS
700	0		_aAhmed Ramadan Mohammed , _eSupervisor
700	0		_aBahaa Eldin Mahmoud Hussein , _eSupervisor
700	0		_aMohamed Fouad Osman , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c82717 _d82717